Anzeige
Mehr »
Sonntag, 19.10.2025 - Börsentäglich über 12.000 News

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
ACCESS Newswire
209 Leser
Artikel bewerten:
(1)

Genhealth AI: GenHealth.ai and Guidehealth Achieve Up to 60% Reduction in Utilization Management Workload Through AI-Native Platform

GenHealth.ai and Guidehealth achieved up to a 60% reduction in Utilization Management workload using GenHealth's AI-native platform, leading to $1.2M in annual savings. The system automates clinical data extraction and policy evaluations, improving efficiency, compliance, and decision consistency above 90%.

BOSTON, MA / ACCESS Newswire / October 17, 2025 / GenHealth.ai, a leader in AI-native healthcare automation, today announced the successful deployment of its AI-driven Utilization Management (UM) and Prior Authorization (PA) platform with Guidehealth, an At Risk Managed Services Organization (MSO). The collaboration resulted in up to 60% reduction in UM workload across multiple care settings, significantly improving efficiency, compliance, and an estimated annual cost savings of $1.2m.

GenHealth.ai x Guidehealth

GenHealth.ai x Guidehealth

GenHealth's AI-native UM platform integrates seamlessly with existing medical guidelines, administrative policies, and provider portals to automate data intake, escalation logic, and decision recommendations-without disrupting existing workflows. During the initial pilot nearly thousands of cases were processed in 4 months before further expansion.

"Healthcare utilization management has long been constrained by manual review and fragmented workflows," said Ethan Siegel, Co-Founder of GenHealth.ai. "Our work with Guidehealth proves that AI can dramatically streamline these processes while maintaining trust, transparency, and full regulatory compliance."

Transforming Utilization Management with Human-Centered AI

GenHealth's solution leverages Large Language Models (LLMs) and predictive algorithms to interpret and apply complex medical and administrative policies. The system automatically extracts, summarizes, and structures clinical data from PDFs, faxes, and call center transcripts-reducing RN manual review time by an average of one hour per Skilled Nursing Facility (SNF) case and accelerating medical policy evaluations to under ten minutes per case.

Each AI-generated recommendation includes detailed citations for every decision step, ensuring complete auditability and compliance with CMS, NCQA, and state-level regulations.

Key Results and Impact

  • Up to 60% workload reduction across utilization management teams

  • 90%+ consistency in decision-making, improving fairness and reducing provider abrasion

  • ~$1.2 million projected annual cost savings across multiple IPAs

  • Full compliance and transparency in AI-assisted medical decision-making

"These results are just the beginning," said Ricky Sahu, CEO and Co-Founder of GenHealth.ai. "As we expand our UM automation capabilities into behavioral health, concurrent review, and SUD services, the impact on efficiency and patient access to care will multiply."

Download the full case study to learn more about the implementation details and outcomes here.

About GenHealth.ai

GenHealth.ai builds AI-native infrastructure for healthcare organizations, empowering payers and providers to automate utilization management, prior authorization, and clinical review processes. By combining large medical models, predictive analytics, and human-centered design, GenHealth enables clients to streamline operations, ensure compliance, and improve patient outcomes.

For more information, visit www.genhealth.ai.

About Guidehealth

Guidehealth is an At Risk Managed Services Organization (MSO) that partners with Independent Physician Associations (IPAs) and provider networks to improve care quality and operational efficiency. The company specializes in value-based care programs, utilization management, and provider engagement strategies. Guidehealth leverages technology and data-driven insights to optimize patient outcomes while supporting clinicians in delivering coordinated, high-quality care

Contact Information

Mike Maseda
Head of Sales & Operations
marketing@genhealth.ai

.

SOURCE: Genhealth AI



View the original press release on ACCESS Newswire:
https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/genhealth.ai-and-guidehealth-achieve-up-to-60-reduction-in-utilizatio-1086751

© 2025 ACCESS Newswire
Solarbranche vor dem Mega-Comeback?
Lange galten Solaraktien als Liebling der Börse, dann kam der herbe Absturz: Zinsschock, Überkapazitäten aus China und ein Preisverfall, der selbst Marktführer wie SMA Solar, Enphase Energy oder SolarEdge massiv unter Druck setzte. Viele Anleger haben der Branche längst den Rücken gekehrt.

Doch genau das könnte jetzt die Chance sein!
Die Kombination aus KI-Explosion und Energiewende bringt die Branche zurück ins Rampenlicht:
  • Rechenzentren verschlingen Megawatt – Solarstrom bietet den günstigsten Preis je Kilowattstunde
  • Moderne Module liefern Wirkungsgrade wie Atomkraftwerke
  • hina bremst Preisdumping & pusht massiv den Ausbau
Gleichzeitig locken viele Solar-Aktien mit historischen Tiefstständen und massiven Short-Quoten, ein perfekter Nährboden für Kursrebound und Squeeze-Rally.

In unserem exklusiven Gratis-Report zeigen wir dir, welche 4 Solar-Aktien besonders vom Comeback profitieren dürften und warum jetzt der perfekte Zeitpunkt für einen Einstieg sein könnte.

Laden Sie jetzt den Spezialreport kostenlos herunter, bevor die Erholung am Markt beginnt!

Dieses Angebot gilt nur für kurze Zeit – also nicht zögern, jetzt sichern!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.